SINTX Technologies Inc (SINT)
0.4602
0.00 (0.00%)
USD |
NASDAQ |
May 25, 12:02
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 11.37M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -67.38% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 18.88 |
| Price to Book Value | 0.7869 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0363 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.99% |
News
Headline
Wire
Time (ET)
Globe Newswire
03/25 17:41
Globe Newswire
03/10 09:00
Globe Newswire
02/23 09:00
Sector Update: Health Care Stocks See Midday Gains Erode as Biotechs Give In to Modest Profit-Taking
MT Newswires
12/31 16:00
MT Newswires
12/31 09:17
Globe Newswire
12/31 09:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/12/2022* | -- | Results | Q2 2022 | -- | -0.11 | -- | |
| 11/12/2021 | -- | Results | Q3 2021 | -0.11 | -0.12 | 4.75% | |
| 08/12/2021 | -- | Results | Q2 2021 | -0.09 | -0.11 | 14.75% | |
| 05/13/2021 | -- | Results | Q1 2021 | -0.11 | -0.09 | -25.89% | |
| 11/16/2020 | -- | Results | Q3 2020 | -0.10 | -0.08 | -22.50% | |
| 08/12/2020 | -- | Results | Q2 2020 | -0.17 | -0.14 | -24.14% | |
| 05/13/2020 | -- | Results | Q1 2020 | -- | -- | -- | |
| 11/21/2017 | 09:00 EST | Earnings Call | Q3 2017 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| SINTX Technologies Inc is a commercial biomaterial company engaged in using its silicon nitride technology platform to develop, manufacture, and sell a range of medical devices. The company derives product revenue primarily from the manufacture and sale of spinal fusion products used in the treatment of spine disorders. It produces silicon nitride for use in commercial products and product candidates in the forms of Solid Silicon Nitride, Porous Silicon Nitride, and Silicon Nitride Powder, among others. It is also engaged in developing wear-and corrosion-resistant implant components for hip and knee arthroplasty. |
| URL | https://www.sintx.com |
| Investor Relations URL | http://investors.amedica.com/ |
| HQ State/Province | Utah |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 12, 2022 (est.) |
| Last Earnings Release | Nov. 12, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of May 24, 2022.
Fundamentals
| Revenue (TTM) | 0.606M |
| Total Expenses (TTM) | 11.26M |
| Net Income (TTM) | -8.987M |
| Total Assets (Quarterly) | 18.88M |
| Total Liabilities (Quarterly) | 4.432M |
| Shareholders Equity (Quarterly) | 14.45M |
| Cash from Operations (TTM) | -10.32M |
| Cash from Investing (TTM) | -2.287M |
| Cash from Financing (TTM) | -0.001M |
Ratings
Profile
Edit
| SINTX Technologies Inc is a commercial biomaterial company engaged in using its silicon nitride technology platform to develop, manufacture, and sell a range of medical devices. The company derives product revenue primarily from the manufacture and sale of spinal fusion products used in the treatment of spine disorders. It produces silicon nitride for use in commercial products and product candidates in the forms of Solid Silicon Nitride, Porous Silicon Nitride, and Silicon Nitride Powder, among others. It is also engaged in developing wear-and corrosion-resistant implant components for hip and knee arthroplasty. |
| URL | https://www.sintx.com |
| Investor Relations URL | http://investors.amedica.com/ |
| HQ State/Province | Utah |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 12, 2022 (est.) |
| Last Earnings Release | Nov. 12, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| SINT Tweets |